How Much Does Farxiga (Dapagliflozin) Cost in Wyoming in 2026?

Wyoming Retail Pricing for Farxiga in 2026

The average cash price for a 30-day supply of Farxiga 10 mg across Wyoming retail pharmacies is $620, matching AstraZeneca's national list price. Wyoming's small population and limited pharmacy competition mean that retail prices rarely dip below this benchmark.

That $620 figure represents the uninsured, undiscounted sticker price. Actual out-of-pocket costs vary based on insurance plan, pharmacy, and discount card use. Patients filling at independent pharmacies in Cheyenne, Casper, or Gillette will generally see the same list price, though some pharmacies may offer modest cash-pay markdowns if asked directly. GoodRx and similar aggregators sometimes list prices between $540 and $610 at select Wyoming locations, but availability fluctuates monthly.

Dapagliflozin does not yet have a generic equivalent on the U.S. Market. AstraZeneca holds patent protection on Farxiga through at least 2027, according to FDA Orange Book records. Until generic competition arrives, Wyoming patients without insurance face a consistent $600+ monthly expense [1].

For context, the DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) compared to placebo [2]. That level of clinical benefit makes cost-of-access questions especially pressing for Wyoming patients with heart failure or CKD who need long-term therapy.

Wyoming Medicaid Does Not Cover Farxiga

Wyoming Medicaid currently does not include Farxiga on its preferred drug list. Patients enrolled in Wyoming Medicaid who need an SGLT2 inhibitor face a coverage gap that requires either a formulary exception request or a switch to an alternative agent.

The state's Medicaid program covers approximately 54,000 residents as of 2026, according to Wyoming Department of Health enrollment data. Wyoming operates a fee-for-service Medicaid model without managed care organizations, which means drug coverage decisions flow directly from the state's Drug Utilization Review (DUR) board. The DUR board has not added Farxiga to the preferred list despite its FDA approvals for type 2 diabetes, heart failure, and CKD.

Physicians can submit a prior authorization request arguing medical necessity. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred second-line therapy for patients with type 2 diabetes who have established cardiovascular disease or CKD (eGFR 20 to 60 mL/min/1.73 m²) [3]. Citing this guideline strengthens prior authorization appeals. Success rates for such appeals in Wyoming Medicaid have not been publicly reported, but the ADA recommendation gives providers a strong clinical justification.

Patients denied Medicaid coverage should ask their prescriber about the AstraZeneca patient assistance program, which covers the full cost of Farxiga for uninsured or underinsured patients meeting income requirements (generally <300% of the federal poverty level).

Commercial Insurance Coverage in Wyoming

Most major commercial insurance plans available in Wyoming do cover Farxiga, though nearly all require prior authorization or step therapy. Expect the drug to sit on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the plan.

Blue Cross Blue Shield of Wyoming, the state's largest insurer, lists Farxiga on its formulary with prior authorization. Patients on BCBS plans typically face copays between $40 and $75 per month after meeting their deductible. UnitedHealthcare plans sold through Wyoming's Health Insurance Marketplace also cover Farxiga but may require documented failure of metformin before approval.

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes management states: "SGLT2 inhibitors should be prioritized for patients with type 2 diabetes and heart failure or chronic kidney disease, independent of glycemic control" [4]. Quoting this guideline in the prior authorization letter may speed approval.

For patients in high-deductible health plans (HDHPs), Farxiga costs count toward the deductible at the full $620 list price until the deductible is met. Wyoming had approximately 38% of its privately insured population in HDHPs as of 2024, based on CDC National Health Interview Survey estimates [5]. These patients benefit most from the manufacturer savings card during the deductible accumulation phase.

A practical coverage checklist for Wyoming patients:

1. Call the number on the back of your insurance card and ask if dapagliflozin (Farxiga) is on formulary
2. Ask what tier it occupies and what the expected copay will be
3. Ask if prior authorization is required and what clinical documentation is needed
4. If denied, request the specific denial reason in writing
5. Have your prescriber submit an appeal citing ADA Standards of Care or Endocrine Society guidelines

The AstraZeneca Savings Card: How It Works in Wyoming

The AstraZeneca Farxiga Savings Card can reduce copays to $0 per month for eligible commercially insured patients. The card covers up to $250 in copay costs per 30-day fill, with a maximum annual benefit of $3,400 per calendar year.

Eligibility rules are straightforward. You must have commercial (private) insurance. Patients on Medicare, Medicaid, Tricare, or other government-funded programs cannot use the card. There is no income requirement. Wyoming residents activate the card online through AstraZeneca's patient portal or by calling the number on the Farxiga prescribing information [1].

Once activated, present the savings card as a secondary payer at any Wyoming pharmacy. The pharmacist runs your primary insurance first, then applies the savings card to the remaining copay. For a patient with a $60 commercial copay, the card would reduce the out-of-pocket to $0. For a patient still in deductible phase paying $620 out of pocket, the card covers $250, leaving $370 to pay.

One limitation: the card does not apply to amounts exceeding $250 per fill. Patients on plans with coinsurance (e.g., 30% of $620 = $186) will likely have their entire copay covered. Patients with no insurance or government insurance need to explore AstraZeneca's separate patient assistance program (AZ&Me), which provides Farxiga at no cost to qualifying households.

Compounded Dapagliflozin in Wyoming: Legal Status and Access

Compounded dapagliflozin is legally available in Wyoming through licensed 503A compounding pharmacies. Wyoming follows federal guidelines under the Drug Quality and Security Act (DQSA), which permits 503A pharmacies to compound patient-specific prescriptions when a valid prescriber-patient relationship exists.

The Wyoming State Board of Pharmacy regulates 503A compounders operating within state lines. These pharmacies can compound dapagliflozin capsules or oral suspensions using bulk pharmaceutical-grade dapagliflozin powder. A key distinction: 503A pharmacies compound on a per-patient basis with an individual prescription, while 503B outsourcing facilities can produce larger batches without patient-specific prescriptions.

Compounded dapagliflozin pricing varies but can be significantly lower than branded Farxiga. Some 503A pharmacies advertise compounded SGLT2 inhibitor formulations for $80 to $200 per month, depending on dose and quantity. Patients should confirm that their chosen pharmacy holds an active Wyoming compounding license and sources dapagliflozin API (active pharmaceutical ingredient) from FDA-registered suppliers [6].

Dr. Robert Califf, former FDA Commissioner, noted in a 2023 FDA statement on compounding: "Compounded drugs are not FDA-approved, and the agency has concerns about quality, potency, and sterility when compounding is performed outside of current good manufacturing practice requirements" [7]. Patients choosing compounded dapagliflozin should discuss quality assurance considerations with their prescriber.

Important caveats: compounded dapagliflozin is not AB-rated as therapeutically equivalent to Farxiga, insurance will not cover it, and the AstraZeneca savings card does not apply to compounded versions.

Getting Farxiga via Telehealth in Wyoming

Telehealth prescribing of Farxiga is legal in Wyoming. The state's telemedicine laws permit licensed physicians and advanced practice providers to prescribe Schedule VI (non-controlled) medications, including dapagliflozin, after a virtual evaluation.

Wyoming passed Senate File 55 in 2020, which established a permanent framework for telehealth practice. Providers must be licensed by the Wyoming Board of Medicine or Board of Nursing. Out-of-state providers can treat Wyoming patients if they hold an active Wyoming license or qualify under the Interstate Medical Licensure Compact, of which Wyoming is a member.

For rural Wyoming patients (the state's population density is just 5.8 persons per square mile), telehealth is often the most practical path to SGLT2 inhibitor therapy. A patient in Thermopolis, Worland, or Lander may be 90+ miles from the nearest endocrinologist. Telehealth platforms that operate in Wyoming can prescribe Farxiga and send the prescription electronically to any Wyoming pharmacy.

Patients using telehealth should have recent lab work available, including HbA1c, serum creatinine, eGFR, and a basic metabolic panel. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) in patients with CKD regardless of diabetes status [8]. These lab values help prescribers determine whether dapagliflozin is appropriate and which FDA-approved indication applies.

Comparing Farxiga to Other SGLT2 Inhibitors in Wyoming

If Farxiga's cost is prohibitive, Wyoming patients may consider alternative SGLT2 inhibitors. The three branded options on the U.S. Market are dapagliflozin (Farxiga), empagliflozin (Jardiance, Boehringer Ingelheim/Lilly), and canagliflozin (Invokana, Janssen).

Jardiance carries a similar list price of approximately $610 to $630 per month. Invokana is priced comparably. None of the three SGLT2 inhibitors has a generic available as of May 2026. Cost differences between them at Wyoming pharmacies are negligible at full retail.

The clinical differentiation matters more than price. Farxiga holds three FDA indications (type 2 diabetes, heart failure with reduced or preserved ejection fraction, and CKD). Jardiance shares the diabetes and heart failure indications but received its CKD indication in 2023 based on the EMPA-KIDNEY trial [9]. The EMPA-KIDNEY trial (N=6,609) demonstrated empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [9].

From a formulary standpoint, some Wyoming insurance plans prefer Jardiance over Farxiga or vice versa. Checking which SGLT2 inhibitor sits on the preferred tier of your specific plan can save $20 to $50 per month in copay differences. If your plan covers Jardiance at Tier 3 but places Farxiga at Tier 4, switching between these clinically similar agents is a reasonable cost-saving strategy. Discuss this with your prescriber.

Tips for Reducing Farxiga Costs in Wyoming

Practical strategies exist for lowering your Farxiga expense in Wyoming, even without strong insurance coverage.

The single most effective step: apply for the AstraZeneca savings card if you have commercial insurance. This alone drops copays to $0 for most patients. For uninsured patients, the AZ&Me patient assistance program provides Farxiga at no cost if household income falls below 300% of the federal poverty level ($46,800 for a single-person household in 2026).

Pharmacy shopping matters less in Wyoming than in more competitive markets, but mail-order pharmacies may offer small savings. Express Scripts, CVS Caremark, and OptumRx mail-order services fill 90-day supplies, which sometimes come with lower per-unit copays than 30-day retail fills. Ask your insurer whether 90-day fills carry a copay advantage.

The 340B Drug Pricing Program could benefit Wyoming patients who receive care at eligible facilities. Wyoming has several 340B-covered entities, including federally qualified health centers in Cheyenne, Casper, and the Wind River Reservation. These sites purchase Farxiga at substantially discounted prices and may pass savings to eligible patients [10].

Prescription discount aggregators (GoodRx, RxSaver, SingleCare) occasionally list Farxiga below $600 at specific Wyoming pharmacies. These prices change weekly. Do not assume a quoted price will hold; confirm at the pharmacy counter before filling.